Apr,2024, Shanghai KeChow Pharma’s Category 1 innovative drug Tunlametinib Capsules (Chinese trade name: KELUPING) was approved with conditions by China NMPA. Tunlametinib Capsules is indicate for patients with NRAS-mutated advanced melanoma who have failed PD-1/PD-L1 treatment[1]https://www.nmpa.gov.cn/zhuanti/cxylqx/cxypxx/20240315082810127.html.
Tunlametinib is a selective mitogen-activated protein kinase 1 and kinase 2 (MEK1/2) kinase inhibitor, which plays an antitumor role by inhibiting the activity of MEK1/2 kinase. The marketing of this drug provides new treatment options for patients with advanced NRAS-mutant melanoma who fail anti- PD-1/PD-L1 therapy.
It is reported that tunlametinib was well tolerated and demonstrated encouraging treatment response rate in pts with advanced NRAS-mutant melanoma. These results indicate that tunlametinib could be a promising treatment option for NRAS-mutant melanoma, even for those immunotherapy failed patients. [2]https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.9510
About Torametinib
Torametinib/HL-085 is a highly selective MEK inhibitor independently developed in my country. It can bind to MEK1/2 in the RAS-RAF-MEK-ERK signaling pathway, block the conduction of downstream signaling pathways, and thus inhibit tumor growth. Colupine can be used for patients with advanced melanoma with NRAS mutations who have failed anti-PD-1/PD-L1 treatment. The recommended dose is 12 mg each time, orally twice a day (approximately once every 12 hours), either on an empty stomach or with meals.
About Shanghai KeChow Pharma Inc
Shanghai KeChow Pharma, Inc. is a clinical-stage biotech focusing on differentiated small molecule therapeutics for cancer. The company was founded by Dr. Hongqi Tian in 2014, and is headquartered in Shanghai Zhangjiang Pharmaceutical Valley. Since its inception, KeChow is committed to accelerate the discovery, development and commercialization of novel small molecule therapeutics through scientific innovation and by leveraging extensive pharmaceutical expertise from the management team. The company has a science driven corporate culture and is specialized in the development of best-in-class innovative therapeutics to address unmet medical needs of patients around the world.
